Literature DB >> 7583580

High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules.

G W Cockerill1, K A Rye, J R Gamble, M A Vadas, P J Barter.   

Abstract

While an elevated plasma concentration of HDLs is protective against the development of atherosclerosis and ensuing coronary heart disease (CHD), the mechanism of this protection is unknown. One early cellular event in atherogenesis is the adhesion of mononuclear leukocytes to the endothelium. This event is mediated principally by vascular cell adhesion molecule-1 (VCAM-1) but also involves other molecules, such as intercellular adhesion molecule-1 (ICAM-1) and E-selectin. We have investigated the effect of isolated plasma HDLs and reconstituted HDLs on the expression of these molecules by endothelial cells. We show that physiological concentrations of HDLs inhibit tumor necrosis factor-alpha (TNF-alpha) or interleukin-1 (IL-1) induction of these leukocyte adhesion molecules in a concentration-dependent manner. Steady state mRNA levels of TNF-alpha-induced VCAM-1 and E-selectin are significantly reduced by physiological concentrations of HDLs. An an HDL concentration of 1 mg/mL apolipoprotein A-I, the protein expressions of VCAM-1, ICAM-1, and E-selectin were inhibited by 89.6 +/- 0.4% (mean +/-SD, n=4), 64.8 +/- 1.0%, and 79.2 +/- 0.4%, respectively. In contrast, HDLs have no effect on the expression of platelet endothelial cell adhesion molecule (PECAM) or on the expression of the p55 and p75 subunits of the TNF-alpha receptor. HDLs were effective when added from 16 hours before to 5 minutes after cytokine stimulation. HDLs had no effect on TNF-alpha-induced expression of ICAM-1 by human foreskin fibroblasts, suggesting that the effect is cell-type restricted.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7583580     DOI: 10.1161/01.atv.15.11.1987

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  167 in total

Review 1.  Inflammation and lipid-lowering treatment.

Authors:  C M Ballantyne; Y Abe
Journal:  Curr Cardiol Rep       Date:  1999-09       Impact factor: 2.931

2.  Targeted deletion of endothelial lipase increases HDL particles with anti-inflammatory properties both in vitro and in vivo.

Authors:  Tetsuya Hara; Tatsuro Ishida; Yoko Kojima; Hanayo Tanaka; Tomoyuki Yasuda; Masakazu Shinohara; Ryuji Toh; Ken-ichi Hirata
Journal:  J Lipid Res       Date:  2010-10-06       Impact factor: 5.922

3.  Ageing, tumour necrosis factor-alpha (TNF-alpha) and atherosclerosis.

Authors:  H Bruunsgaard; P Skinhøj; A N Pedersen; M Schroll; B K Pedersen
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

Review 4.  Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.

Authors:  Martin Hersberger; Arnold von Eckardstein
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 5.  The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?

Authors:  Menno Vergeer; Adriaan G Holleboom; John J P Kastelein; Jan Albert Kuivenhoven
Journal:  J Lipid Res       Date:  2010-04-06       Impact factor: 5.922

Review 6.  Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.

Authors:  K Mahdy Ali; A Wonnerth; K Huber; J Wojta
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

7.  Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure.

Authors:  Guoqing Cao; Thomas P Beyer; Youyan Zhang; Robert J Schmidt; Yan Q Chen; Sandra L Cockerham; Karen M Zimmerman; Sotirios K Karathanasis; Ellen A Cannady; Todd Fields; Nathan B Mantlo
Journal:  J Lipid Res       Date:  2011-09-25       Impact factor: 5.922

Review 8.  Dysfunctional high-density lipoprotein and atherosclerosis.

Authors:  Shawn Ragbir; John A Farmer
Journal:  Curr Atheroscler Rep       Date:  2010-09       Impact factor: 5.113

9.  HDL Cholesterol Efflux Predicts Graft Failure in Renal Transplant Recipients.

Authors:  Wijtske Annema; Arne Dikkers; Jan Freark de Boer; Robin P F Dullaart; Jan-Stephan F Sanders; Stephan J L Bakker; Uwe J F Tietge
Journal:  J Am Soc Nephrol       Date:  2015-08-28       Impact factor: 10.121

Review 10.  Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention.

Authors:  Maureen McMahon; Bevra H Hahn; Brian J Skaggs
Journal:  Expert Rev Clin Immunol       Date:  2011-03       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.